Abstract/References

Drug treatment for chemotherapy-induced peripheral neuropathy in patients with pancreatic cancer

Mitsuru Sugimoto, Tadayuki Takagi, Rei Suzuki, Naoki Konno, Hiroyuki Asama, Yuki Sato, Hiroki Irie, Yoshinori Okubo, Jun Nakamura, Mika Takasumi, Minami Hashimoto, Tsunetaka Kato, Ryoichiro Kobashi, Takuto Hikichi, Hiromasa Ohira

Abstract

Pancreatic cancer (PC) is a lethal disease where most tumors are too advanced at diagnosis for resection, leaving chemotherapy as the mainstay of treatment. Although the prognosis of unresectable PC is poor, it has been dramatically improved by new chemotherapy treatments, such as the combination of 5-fluorouracil, oxaliplatin, irinotecan, and leucovorin (FOLFIRINOX) or gemcitabine plus nab-paclitaxel. However, as oxaliplatin and paclitaxel are common neurotoxic drugs, chemotherapy-induced peripheral neuropathy (CIPN) is a common and severe adverse effect of both treatments. As there are no agents recommended in the ASCO guidelines, we review the methods used to treat CIPN caused by PC treatment. The efficacy of duloxetine was observed in a large randomized controlled trial (RCT). In addition, pregabalin was more effective than duloxetine for CIPN in two RCTs. Although duloxetine and pregabalin can be effective for CIPN, they have several side effects. Therefore, the choice between the two drugs should be determined according to effect and tolerability. Mirogabalin is also used in patients with PC and there is hope it will yield positive outcomes when treating CIPN in the future.

The content of research paper

References

1. 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 68:394-424, 2018.
2. 2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin, 70:7-30, 2020.
3. 3. Afshar N, English DR, Chamberlain JA, et al. Differences in cancer survival by remoteness of residence:an analysis of data from a population-based cancer registry. Cancer Causes Control, 31:617-629, 2020.
4. Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol, 7:163-172, 2010.
5. Warsame R, Grothey A. Treatment options for advanced pancreatic cancer:a review. Expert Rev Anticancer Ther, 12:1327-1336, 2012.
6. Fogel EL, Shahda S, Sandrasegaran K, et al. A Multidisciplinary Approach to Pancreas Cancer in 2016:A Review. Am J Gastroenterol, 112:537-554, 2017.
7. 7. Suker M, Beumer BR, Sadot E, et al. FOLFIRINOX for locally advanced pancreatic cancer:a systematic review and patient-level meta-analysis. Lancet Oncol, 17:801-810, 2016.
8. 8. Thibodeau S, Voutsadakis IA. FOLFIRINOX chemotherapy in metastatic pancreatic cancer:a systematic review and meta-analysis of retrospective and phase II studies. J Clin Med, 7:7, 2018.
9. Zhang Y, Xu J, Hua J, et al. Nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic cancer:a systematic review and meta-analysis. J Cancer, 10:4420-4429, 2019.
10. Lorgis V, Chauffert B, Gentil J, Ghiringhelli F. Influcence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study. Anticancer Res, 32:4125-4130, 2012.
11. Tong H, Fan Z, Liu B, Lu T. The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events:a systematic review and meta-analysis. Sci Rep, 8:8666, 2018.
12. 12. Loprinzi CL, Reeves BN, Dakhil SR, et al. Natural history of paclitaxel-associated acute pain syndrome:prospective cohort study NCCTG N08C1. J Clin Oncol, 29:1472-1478, 2011.
13. 13. Reeves BN, Dakhil SR, Sloan JA, et al. Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy:North Central Cancer Treatment Group trial N08C1. Cancer, 118:5171-5178, 2012.
14. Pachman DR, Qin R, Seisler DK, et al. Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance). J Clin Oncol, 33:3416-3422, 2015.
15. 15. Loprinzi CL, Lacchetti C, Bleeker J, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers:ASCO guideline update. J Clin Oncol, 38:3325-3348, 2020.
16. Morfini GA, Burns M, Binder LI, et al. Axonal transport defects in neurodegenerative diseases. J Neurosci, 29:12776-12786, 2009.
17. Gill JS, Windebank AJ. Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. J Clin Invest, 101:2842-2850, 1998.
18. 18. McDonald ES, Windebank AJ. Cisplatin-induced apoptosis of DRG neurons involves bax redistribution and cytochrome c release but not fas receptor signaling. Neurobiol Dis, 9:220-233, 2002.
19. Rowinsky EK, Chaudhry V, Cornblath DR, Donehower RC. Neurotoxicity of taxol. J Natl Cancer Inst Monogr, 107-115, 1993.
20. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol, 20:1-15, 1993.
21. Gogas H, Shapiro F, Aghajanian C, et al. The impact of diabetes mellitus on the toxicity of therapy for advanced ovarian cancer. Gynecol Oncol, 61:22-26, 1996.
22. 22. Schneider BP, Zhao F, Wang M, et al. Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer. J Clin Oncol, 30: 3051-3057, 2012.
23. Schneider BP, Li L, Radovich M, et al. Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199. Clin Cancer Res, 21:5082-5091, 2015.
24. Bao T, Basal C, Seluzicki C, Li SQ, Seidman AD, Mao JJ. Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk.　Breast Cancer Res Treat, 159: 327-333, 2016.
25. 25. Smith EM, Beck SL, Cohen J. The total neuropathy score:a tool for measuring chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum, 35:96-102, 2008.
26. 26. Stubblefield MD, McNeely ML, Alfano CM, Mayer DK. A prospective surveillance model for physical rehabilitation of women with breast cancer: chemotherapy-induced peripheral neuropathy. Cancer, 118:2250-2260, 2012.
27. 27. Ishibashi K, Okada N, Miyazaki T, Sano M, Ishida H. Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy:a prospective randomized study. Int J Clin Oncol, 15:82-87, 2010.
28. 28. Loprinzi CL, Qin R, Dakhil SR, et al. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol, 32:997-1005, 2014.
29. 29. Oki E, Emi Y, Kojima H, et al. Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial):a placebo-controlled, double-blind, randomized phase III study.　Int J Clin Oncol, 20:767-775, 2015.
30. 30. Smith EM, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy:a randomized clinical trial.　JAMA, 309:1359-1367, 2013.
31. 31. de Andrade DC, Jacobsen Teixeira M, Galhardoni R, et al. Pregabalin for the Prevention of Oxaliplatin-Induced Painful Neuropathy: A Randomized, Double-Blind Trial. Oncologist, 22:1154-e1105, 2017.
32. Avan R, Janbabaei G, Hendouei N, et al. The effect of pregabalin and duloxetine treatment on quality of life of breast cancer patients with taxane-induced sensory neuropathy:a randomized clinical trial. J Res Med Sci, 23:52, 2018.
33. 33. Salehifar E, Janbabaei G, Hendouei N, Alipour A, Tabrizi N, Avan R. Comparison of the efficacy and safety of pregabalin and duloxetine in taxane-induced sensory neuropathy:a randomized controlled trial. Clin Drug Investig, 40:249-257, 2020.
34. 34. Rao RD, Michalak JC, Sloan JA, et al. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy:a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer, 110:2110-2118, 2007.
35. 35. Hirayama Y, Ishitani K, Sato Y, et al. Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy:a pilot randomized trial. Int J Clin Oncol, 20:866-871, 2015.
36. Wang J, Li Q, Xu B, Zhang T, Chen S, Luo Y. Efficacy and safety of duloxetine in Chinese breast cancer patients with paclitaxel-induced peripheral neuropathy. Chin J Cancer Res, 29:411-418, 2017.
37. 37. Hincker A, Frey K, Rao L, et al. Somatosensory predictors of response to pregabalin in painful chemotherapy-induced peripheral neuropathy:a randomized, placebo-controlled, crossover study.　Pain, 160:1835-1846, 2019.
38. 38. Armstrong CM, Cota G. Calcium block of Na+ channels and its effect on closing rate. Proc Natl Acad Sci U S A, 96:4154-4157, 1999.
39. 39. Wesselink E, Winkels RM, van Baar H, et al. Dietary intake of magnesium or calcium and chemotherapy-induced peripheral neuropathy in colorectal cancer patients. Nutrients, 10:398, 2018.
40. 40. Kaku H, Kumagai S, Onoue H, et al. Objective evaluation of the alleviating effects of Goshajinkigan on peripheral neuropathy induced by paclitaxel/carboplatin therapy:A multicenter collaborative study. Exp Ther Med, 3:60-65, 2012.
41. 41. Kono T, Hata T, Morita S, et al. Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE):a phase 2, multicenter, randomized, doubleblind, placebocontrolled trial of Goshajinkigan to prevent oxaliplatininduced neuropathy. Cancer Chemother Pharmacol, 72:1283-1290, 2013.
42. 42. Nishioka M, Shimada M, Kurita N, et al. The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen. Int J Clin Oncol, 16:322-327, 2011.
43. 43. Willis WD, Westlund KN. Neuroanatomy of the pain system and of the pathways that modulate pain. J Clin Neurophysiol, 14:2-31, 1997.
44. 44. Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers:American society of clinical oncology clinical practice guideline. J Clin Oncol, 32:1941-1967, 2014.
45. 45. Schloss JM, Colosimo M, Airey C, Masci P, Linnane AW, Vitetta L. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN). Support Care Cancer, 25:195-204, 2017.
46. 46. Xiao W, Boroujerdi A, Bennett GJ, Luo ZD. Chemotherapy-evoked painful peripheral neuropathy: analgesic effects of gabapentin and effects on expression of the alpha-2-delta type-1 calcium channel subunit. Neuroscience, 144:714-720, 2007.
47. 47. Gauchan P, Andoh T, Ikeda K, et al. Mechanical allodynia induced by paclitaxel, oxaliplatin and vincristine:different effectiveness of gabapentin and different expression of voltage-dependent calcium channel alpha(2)delta-1 subunit. Biol Pharm Bull, 32:732-734, 2009.
48. 48. Peng P, Xi Q, Xia S, et al. Pregabalin attenuates docetaxel-induced neuropathy in rats. J Huazhong Univ Sci Technolog Med Sci, 32:586-590, 2012.
49. 49. Aoki M, Kurauchi Y, Mori A, Nakahara T, Sakamoto K, Ishii K. Comparison of the effects of single doses of elcatonin and pregabalin on oxaliplatin-induced cold and mechanical allodynia in rats. Biol Pharm Bull, 37:322-326, 2014.
50. 50. Shinde SS, Seisler D, Soori G, et al. Can pregabalin prevent paclitaxel-associated neuropathy? An ACCRU pilot trial. Support Care Cancer, 24:547-553, 2016.
51. 51. Field MJ, Oles RJ, Lewis AS, McCleary S, Hughes J, Singh L. Gabapentin (neurontin) and S-(+)-3-isobutylgaba represent a novel class of selective antihyperalgesic agents. Br J Pharmacol, 121:1513-1522, 1997.
52. 52. Shimoyama M, Shimoyama N, Hori Y. Gabapentin affects glutamatergic excitatory neurotransmission in the rat dorsal horn. Pain, 85:405-414, 2000.
53. 53. Luo ZD, Chaplan SR, Higuera ES, et al. Upregulation of dorsal root ganglion (alpha)2(delta) calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats. J Neurosci, 21: 1868-1875, 2001.
54. 54. Lynch JJ, 3rd, Wade CL, Zhong CM, Mikusa JP, Honore P. Attenuation of mechanical allodynia by clinically utilized drugs in a rat chemotherapy-induced neuropathic pain model. Pain, 110:56-63, 2004.
55. 55. Ling B, Authier N, Balayssac D, Eschalier A, Coudore F. Behavioral and pharmacological description of oxaliplatin-induced painful neuropathy in rat. Pain, 128:225-234, 2007.
56. 56. Magnowska M, Iżycka N, Kapoła-Czyż J, et al. Effectiveness of gabapentin pharmacotherapy in chemotherapy-induced peripheral neuropathy.　Ginekol Pol, 89:200-204, 2018.
57. 57. Aghili M, Zare M, Mousavi N, et al. Efficacy of gabapentin for the prevention of paclitaxel induced peripheral neuropathy: A randomized placebo controlled clinical trial. Breast J, 25:226-231, 2019.
58. 58. You MS, Ryu JK, Choi YH, et al. Efficacy of Nab-paclitaxel plus gemcitabine and prognostic value of peripheral neuropathy in patients with metastatic pancreatic cancer. Gut Liver, 12:728-735, 2018.
59. Catalano M, Aprile G, Ramello M, Conca R, Petrioli R, Roviello G. Association between low-grade chemotherapy-induced peripheral neuropathy (CINP) and survival in patients with metastatic adenocarcinoma of the pancreas. J Clin Med, 10:1846, 2021.
60. 60. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med, 369:1691-1703, 2013.
61. 61. Baba M, Matsui N, Kuroha M, Wasaki Y, Ohwada S. Mirogabalin for the treatment of diabetic peripheral neuropathic pain:A randomized, double-blind, placebo-controlled phase III study in Asian patients. J Diabetes Investig, 10:1299-1306, 2019.
62. 62. Sugimoto M, Takagi T, Suzuki R, et al. Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients.　BMC Cancer, 21:1319, 2021.

Figures (1)